OBJECTIVE: Cystatin C, a novel marker of kidney function, has been reported to be a predictor of adverse cardiovascular outcomes in patients without established chronic kidney disease. However, the relationship between serum cystatin C concentrations and early stage coronary atherosclerotic plaque morphology among patients with preserved kidney function has not been fully evaluated. METHODS AND RESULTS: 405 outpatients with early coronary artery disease with estimated glomerular filtration rate (eGFR) ≥ 60ml/min/1.73m(2) and <50% stenosis on 64-slice CT coronary angiography were enrolled. Subjects were categorized into quartiles by serum cystatin C (quartile I: ≤ 0.88mg/L - quartile IV: ≥ 1.16mg/L). Plaques in coronary segments were categorized as calcified or noncalcified. Multiple linear regression analysis revealed that lower eGFR, higher age, increasing numbers of noncalcified and calcified plaques, lower high-density lipoprotein cholesterol, and female gender were statistically significant predictors of increased cystatin C concentrations. The risk for presence of noncalcified plaques increased significantly with increasing quartiles of cystatin C. Compared with those in the lowest quartile, patients in each subsequent quartile were at steadily increased risk of having noncalcified plaque (quartile IV: OR 5.6; 95% CI 2.3-13.9, p-value <0.001). Both number of segments with calcified plaque and Agatston score were highly correlated with cystatin C concentrations (both p<0.001), but when adjusted for segments with noncalcified plaque and other risk factors, calcified plaque segments were no longer independently predictive. CONCLUSION: Higher serum cystatin C concentrations were correlated with early stage coronary atherosclerotic plaques among patients without established chronic kidney dysfunction. Noncalcified plaques increased with serum cystatin C concentrations, an association independent of eGFR and other cardiovascular risk factors.
OBJECTIVE:Cystatin C, a novel marker of kidney function, has been reported to be a predictor of adverse cardiovascular outcomes in patients without established chronic kidney disease. However, the relationship between serum cystatin C concentrations and early stage coronary atherosclerotic plaque morphology among patients with preserved kidney function has not been fully evaluated. METHODS AND RESULTS: 405 outpatients with early coronary artery disease with estimated glomerular filtration rate (eGFR) ≥ 60ml/min/1.73m(2) and <50% stenosis on 64-slice CT coronary angiography were enrolled. Subjects were categorized into quartiles by serum cystatin C (quartile I: ≤ 0.88mg/L - quartile IV: ≥ 1.16mg/L). Plaques in coronary segments were categorized as calcified or noncalcified. Multiple linear regression analysis revealed that lower eGFR, higher age, increasing numbers of noncalcified and calcified plaques, lower high-density lipoprotein cholesterol, and female gender were statistically significant predictors of increased cystatin C concentrations. The risk for presence of noncalcified plaques increased significantly with increasing quartiles of cystatin C. Compared with those in the lowest quartile, patients in each subsequent quartile were at steadily increased risk of having noncalcified plaque (quartile IV: OR 5.6; 95% CI 2.3-13.9, p-value <0.001). Both number of segments with calcified plaque and Agatston score were highly correlated with cystatin C concentrations (both p<0.001), but when adjusted for segments with noncalcified plaque and other risk factors, calcified plaque segments were no longer independently predictive. CONCLUSION: Higher serum cystatin C concentrations were correlated with early stage coronary atherosclerotic plaques among patients without established chronic kidney dysfunction. Noncalcified plaques increased with serum cystatin C concentrations, an association independent of eGFR and other cardiovascular risk factors.
Authors: Min Ji Shin; Sang Heon Song; Ihm Soo Kwak; Soo Bong Lee; Dong Won Lee; Eun Young Seong; Il Young Kim; Harin Rhee; Naria Lee Journal: Clin Exp Nephrol Date: 2012-01-26 Impact factor: 2.801
Authors: Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón Journal: J Bone Miner Metab Date: 2015-08-23 Impact factor: 2.626
Authors: Anjali Ganda; Martin Magnusson; Laurent Yvan-Charvet; Bo Hedblad; Gunnar Engström; Ding Ai; Thomas J Wang; Robert E Gerszten; Olle Melander; Alan R Tall Journal: Circulation Date: 2013-02-01 Impact factor: 29.690
Authors: Olivera Marsenic; Andrea Wierenga; Donna R Wilson; Michael Anderson; Tripti Shrivastava; Garfield A Simon; Anne M Beck; Tiffany J Swanson; Kathleen Studnicka; Dorit Elberg; Kevin Couloures; Martin A Turman Journal: Pediatr Nephrol Date: 2012-11-21 Impact factor: 3.714
Authors: C M Gijsberts; A Seneviratna; I E M Bank; H M den Ruijter; F W Asselbergs; P Agostoni; J A Remijn; G Pasterkamp; H C Kiat; M Roest; A M Richards; M Y Chan; D P V de Kleijn; I E Hoefer Journal: Neth Heart J Date: 2016-03 Impact factor: 2.380
Authors: Natalia G Vallianou; Vassiliki P Bountziouka; Ekavi Georgousopoulou; Angelos A Evangelopoulos; Maria S Bonou; Evangelos D Vogiatzakis; John D Barbetseas; Peter C Avgerinos; Demosthenes B Panagiotakos Journal: J Health Popul Nutr Date: 2013-12 Impact factor: 2.000